AEZS Disappoints, EVOK Gets New Lease Of Life, GNMX Calls For Attention

Shares of Aeterna Zentaris Inc. (AEZS) plunged over 39% in extended trading on Wednesday on disappointing results from its phase III trial of Macrilen.

from RTT - Biotech http://ift.tt/2jcqe4u
via IFTTT